KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy
作者： Terry Mashtare , Marwan Fakih , Maher Saifo , Ila R Tamaskar , Ramkumar Bhuvaneswari
DOI: 10.3978/J.ISSN.2078-6891.2010.022
关键词:
摘要: Background: Two previous first-line studies showed an improved trend in response rate (RR) and progression free survival (PFS) metastatic colorectal cancer (CRC) patients with KRAS mutation. Others have reported a worsened outlook for CRC mutation higher likelihood of disease to the lungs. In this study, we aimed address impact on pattern at presentation RR PFS 5-fluorouracil, leucovorin, oxaliplatin (FOLFOX) chemotherapy. Methods: Patients who underwent testing using DxS assay Roswell Park Cancer Institute (RPCI) were identified. treated FOLFOX +/- bevacizumab assessed RECIST 1.1 guidelines. A two-sided Fisher\'s exact test was used determine statistical significance. Results: 181 83/181 (+/- bevacizumab) setting RPCI evaluable as per study (MT) occurred 40.31% cases. There no difference organ-metastases distribution, (56.60% wild-type (WT) 50% mutant) or (9.3 months WT 8.7 MT) based status. Conclusion: single institute our findings do not support any predictive role KRAS-MT terms chemotherapy, sites mCRC presentation.
amegroups.com参考文章(26)
G. I Meling, P Laurent-Puig, B. J Iacopetta, R Glaesener, O. P. F Clausen, F Al-Mulla, W Giaretti, V. J Bubb, A. F. P. M de Goeij, G Gaudernack, T Ohkusa, P Quirke, A Rapallo, N Hawkins, R Rosell, T. O Rognum, S. N Andersen, R Smith, J Costa, R Ward, I Hoffmann, T Fujimori, D Cunningham, D Morton, C. T Croke, J Oates, X. F Sun, S Bell, P. A Clarke, S. T Wang, J Breivik, O Muller, A. R Norman, J. W Arends, M Pauly, D Dillon, H. J. N Andreyev, S. D Finkelstein, A. J Senagore, C. N Hall, K Wilkinson, N Lees, N. R Cruickshank, H. S Goh, D Snary, E Jullian, C Valavanis, L Losi, A Russo, H. M Rabes, J Piris, S Wadler, Y Ono, T Azuma, A Font, C Zietz, M Beranek, J. C Fox, S. A Halter, R Benamouzig, B. R Dix, H Zhang, C Faber, K Omura, V. E Pricolo, C Troungos, K Krtolica, J Benhattar, J. W. C Ho, N. Urosevic, T Lovig, D. P O'Donoghue, J. S Thebo, P De Angelis, J. Q Lee, J Young, Bazan, P Jandik, S Olschwang, S. T Yuen, T Walsh, S Malik, M Tanaka, Kirsten ras mutations in patients with colorectal cancer : the ‘RASCAL II’ study Faculty of Health; Institute of Health and Biomedical Innovation. ,vol. 85, pp. 692- 696 ,(2001)
Sandra M. Bell, Nigel Scott, Debra Cross, Peter Sagar, Fraser A. Lewis, G.Eric Blair, Graham R. Taylor, Michael F. Dixon, Philip Quirke, Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer Gastroenterology. ,vol. 104, pp. 57- 64 ,(1993) , 10.1016/0016-5085(93)90835-Z
S.J. Leevers, C.J. Marshall, Activation of extracellular signal-regulated kinase, ERK2, by p21ras oncoprotein. The EMBO Journal. ,vol. 11, pp. 569- 574 ,(1992) , 10.1002/J.1460-2075.1992.TB05088.X
Laila Buø, Gunn Iren Meling, Tove S Karlsrud, Harald T Johansen, Ansgar O Aasen, Antigen levels of urokinase plasminogen activator and its receptor at the tumor-host interface of colorectal adenocarcinomas are related to tumor aggressiveness. Human Pathology. ,vol. 26, pp. 1133- 1138 ,(1995) , 10.1016/0046-8177(95)90276-7
Kenneth W. Wood, Charlyn Sarnecki, Thomas M. Roberts, John Blenis, ras mediates nerve growth factor receptor modulation of three signal-transducing protein kinases: MAP kinase, Raf-1, and RSK Cell. ,vol. 68, pp. 1041- 1050 ,(1992) , 10.1016/0092-8674(92)90076-O
Neelesh Sharma, Hirofumi Suzuki, Quanren He, Raghubir P. Sharma, Tumor necrosis factor alpha-mediated activation of c-Jun NH(2)-terminal kinase as a mechanism for fumonisin B(1) induced apoptosis in murine primary hepatocytes. Journal of Biochemical and Molecular Toxicology. ,vol. 19, pp. 359- 367 ,(2006) , 10.1002/JBT.20102
Paloma Cejas, Miriam Lopez-Gomez, Cristina Aguayo, Rosario Madero, Javier de Castro Carpeno, Cristobal Belda-Iniesta, Jorge Barriuso, Victor Moreno Garcia, Javier Larrauri, Rocío López, Enrique Casado, Manuel Gonzalez-Baron, Jaime Feliu, None, KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLOS ONE. ,vol. 4, pp. 8199- ,(2009) , 10.1371/JOURNAL.PONE.0008199
Eric R. Fearon, Bert Vogelstein, A genetic model for colorectal tumorigenesis Cell. ,vol. 61, pp. 759- 767 ,(1990) , 10.1016/0092-8674(90)90186-I
Neelesh Sharma, Quanren He, Raghubir P. Sharma, Sphingosine kinase activity confers resistance to apoptosis by fumonisin B1 in human embryonic kidney (HEK-293) cells. Chemico-Biological Interactions. ,vol. 151, pp. 33- 42 ,(2004) , 10.1016/J.CBI.2004.10.003
E.A. Eisenhauer, P. Therasse, J. Bogaerts, L.H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe, J. Verweij, New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) European Journal of Cancer. ,vol. 45, pp. 228- 247 ,(2009) , 10.1016/J.EJCA.2008.10.026